Clinical course and prognosis of dilated cardiomyopathy in children
DOI:
https://doi.org/10.18203/2320-6012.ijrms20194995Keywords:
Children, Dilated cardiomyopathy, Dyspnoea, Fatigue, Myocarditis, PrognosisAbstract
Background: Epidemiology and clinical course of dilated cardiomyopathy (DCM) in children and infants are not well established. Thus, this study aims to investigate the clinical course and prognosis of DCM in children
Methods: This was a single-center, prospective, observational study conducted at a tertiary-care center in India between February 2011 and September 2012. A total of 31 patients admitted to the paediatric department diagnosed with DCM were included in the study. Patients were divided into three groups based on the age at the time of diagnosis: 0-3 years, >3-12 years and >12-16 years. Among the study population, 28 patients were followed up for a mean period of 1.44 years and three patients were lost to follow-up.
Results: Of the 31 patients, 11 patients were male with a mean age of 8.9±6 years and 20 patients were female with a mean age of 8.3±6 years. All patients were presented with same characteristics of New York heart association (NYHA) class III-IV dyspnoea and fatigue. Among 28 patients who were followed-up for a mean period of 1.44 years, 20(71.4%) patients died and eight patients were on follow up. Of the eight patients, five patients were with NYHA class III symptoms and three patients were with NYHA class I-II symptoms.
Conclusions: Dilated cardiomyopathy in children is a very serious disease with a grave prognosis. Patients with NYHA III-IV symptoms have a very high mortality rate and potential use of other therapies remains to be fully evaluated in paediatric population.
References
Richadson P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology. Task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-2.
Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela A-L, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents: a nationwide study in Finland. Am J Epidemiol. 1997;146:385-93.
Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867-76.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113(14):1807-16.
Ferencz C, Neill CA. Cardiomyopathy in infancy: observations in an epidemiologic study. Pediatr Cardiol. 1992;13(2):65-71.
Shaddy RE. Cardiomyopathies in adolescents: dilated, hypertrophic, and restrictive. Adolescent Med Clin. 2001;12(1):35.
Lewis AB. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. Am Heart J. 1999;138:334-8.
Helton E, Darragh R, Francis P, Fricker FJ, Jue K, Koch G, et al. Metabolic Aspects of Myocardial Disease and a Role forl-Carnitine in the Treatment of Childhood Cardiomyopathy. Pediatrics. 2000;105:1260-70.
Stern H, Weil J, Genz T, Vogt W, Bühlmeyer K. Captopril in children with dilated cardiomyopathy: acute and long-term effects in a prospective study of hemodynamic and hormonal effects. Pediatr Cardiol. 1990;11:22-8.
Bruns LA, Canter CE. Should β-blockers be used for the treatment of pediatric patients with chronic heart failure? Pediatr Drugs. 2002;4(12):771-8.
Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647-55.
Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639-46.
Kothari S, Dhopeshwarkar R, Saxena A, Juneja R. Dilated cardiomyopathy in Indian children. Indian Heart J. 2003;55(2):147-51.
Khalil A, Chawla K, Chakravarti A. Dilated cardiomyopathy: clinical profile and treatment. Indian Pediatr. 2000;37:1242-6.
Tsirka AE, Trinkaus K, Chen S-C, Lipshultz SE, Towbin JA, Colan SD, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol. 2004;44:391-7.
McDonagh T, Cunningham A, Morrison C, McMurray J, Ford I, Morton J, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 2001;86:21-6.
Akagi T, Benson LN, Lightfoot NE, Chin K, Wilson G, Freedom RM. Natural history of dilated cardiomyopathy in children. Am Heart J. 1991;121:1502-6.
Schwartz ML, Cox GF, Lin AE, Korson MS, Perez-Atayde A, Lacro RV, et al. Clinical approach to genetic cardiomyopathy in children. Circulation. 1996;94:2021-38.
BILGIÇ A, ÖZBARLAS N, ÖZKUTLU S, ÖZER S, ÖZME S. Cardiomyopathies in Children Clinical, Epidemiological and Prognostic Evaluation. Japanese Heart J. 1990;31:789-97.
Lewis AB, Chabot M. Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol. 1991;68(4):365-9.
McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-9.
McMahon C, Nagueh S, Eapen R, Dreyer W, Finkelshtyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90:908-15.
Rosenthal D, Chrisant MR, Edens E, Mahony L, Canter C, Colan S, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant. 2004;23(9):1313-33.
